DELVE INTO AFRICAN WEALTH
DON'T MISS A BEAT
Subscribe now
Skip to content

Kenneth Frazier’s Merck holdings rebound, surpassing $90 million amid stock rally

Frazier’s holdings in Merck took a hit earlier this month, but a recent surge in the company’s share price has recouped those losses.

Kenneth Frazier
Kenneth Frazier

Table of Contents

Kenneth Frazier, one of America’s prominent Black executives, has recouped some of his recent portfolio losses as Merck & Co.’s shares rebound strongly, pushing the market value of his stake in the pharmaceutical giant above $90 million.

The rebound comes after Merck’s stock price rallied on the New York Stock Exchange (NYSE). Over the past 10 days, the company’s shares have seen a notable increase, boosting Frazier’s holding by $3.99 million and pushing it back over $90 million.

Kenneth Frazier’s holdings in Merck took a hit earlier this month, but a recent surge in the company’s share price has recouped those losses. Between April 1 and 12, the market value of his stake declined by $3.4 million, falling from $92.38 million to $89.01 million.

Merck rebounds after early month slide

Healthcare giant Merck remains a leader in the pharmaceutical industry, offering a diverse portfolio of prescription drugs, vaccines, biological therapies, animal health products, and consumer healthcare solutions. The company operates through three segments: Pharmaceutical, Animal Health, and Other.

Merck’s stock has seen a reversal of fortune in the past ten days, following a significant decline earlier this month. The share price has risen 4.53 percent, climbing from $125.06 on April 16 to $130.7 as of April 25. This surge has pushed Merck’s market capitalization above $330 billion and delivered substantial gains to shareholders.

The recent rally is attributed to higher-than-expected sales of Merck’s blockbuster cancer drug, Keytruda. Sales of Keytruda soared 20 percent year-over-year in the first quarter, reaching $6.9 billion compared to $5.8 billion in the prior-year period. This surpassed Wall Street analysts’ expectations of $6.7 billion, based on a consensus estimate from analysts surveyed by FactSet.

Frazier’s stake in Merck & Co. soars

Kenneth Frazier, a prominent African American executive, holds a 0.028-percent stake in the New Jersey-based pharmaceutical company, currently valued at $92.19 million. This makes him one of the most affluent Black executives in the U.S.

According to data tracked by Billionaires.Africa, the market value of Frazier’s stake in Merck & Co. has risen by $3.99 million over the past 10 days, rising from $88.19 million on April 16 to $92.19 million as of reporting.

The recent upsurge in Merck & Co.’s stock price underscores both Frazier’s longstanding presence as a shareholder and the company’s commitment to innovation and sustainable healthcare solutions, which continue to attract investors.

Latest